US · Healthcare · Medical Devices
EPS came in at 1.13 against a street estimate of 1.04 — a beat of 8.7%.
Analysts rate GE HealthCare Technologies Inc. a buy (16 buy, 5 hold, 0 sell out of 21) with an average price target of $82.70.
CONFIDENT Strong orders growth (11% YoY) and record backlog ($23.9B) offset PCS weakness. PDX surged 14.6%; AIS grew 5%. Management confident in 2028 $500M radiopharmaceutical target and mid-term guidance despite supply-chain challenges in monitoring/anesthesia. Q2 2026 All regions showed reported revenue growth. China decline assumed prudent for 2026 given VBP expansion; no surprises. Europe benefiting from imaging strength. Analysts pressed on orders sustainability, valuation vs. street EPS, and competitive threats (generics, China). Management emphasized broad-based order growth (not one-time), retained commodity cushion in guidance, and trusted supplier moat in contrast. CFO departure (Jay Saccaro to new role) surprised; interim CFO George Nukem to lead; search underway—no timeline given. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| Dodge & Cox | 8.38% |
| BlackRock Inc | 8.30% |
| Vanguard Capital Management, LLC | 6.58% |
| State Street Corp | 4.62% |
| Vanguard Portfolio Management, LLC | 4.49% |
| Amvescap Plc. | 4.05% |
| Harris Associates L.P. | 3.39% |
| Barrow Hanley Mewhinney & Strauss LLC | 2.98% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 GE HEALTHCARE TECHNOLOGIES INC. - DOCUMENT SUMMARY OTHER NOTABLE POINTS • Director Appointment: Pascal Desroches appointed to the Board of Directors | 2026-09-22 |
| Board / officer change · Q3 2026 GE HEALTHCARE TECHNOLOGIES INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • New CFO appointment effective September 14, 2026 • Total compensation package: | 2026-08-18 |
| Quarterly report · Q2 2026 GE HEALTHCARE TECHNOLOGIES INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q2 2026: $5,295 million (vs. $5,007 million Q2 2025) — up 5 | 2026-07-29 |
| Reg FD disclosure · Q3 2026 GE HEALTHCARE TECHNOLOGIES INC. — FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company restructured its operating segments in Q2 2026, combining | 2026-07-29 |
| Results announced · Q3 2026 GE HEALTHCARE Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue of $5.3 billion, up 5.7% year-over-year; organic revenue growth of 3.5% • Ne | 2026-07-29 |
| Results announced · Q3 2026 GE HEALTHCARE Q2 2026 PRELIMINARY RESULTS & CFO TRANSITION HEADLINE NUMBERS • Total Revenue: $5,295 million in Q2 2026, up 5.7% year-over-year • Org | 2026-07-23 |
| Quarterly report · Q1 2026 GE HEALTHCARE TECHNOLOGIES INC. — Q1 2026 SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $5,131 million (up 7.4% vs Q1 2025: $4,777 million) - | 2026-04-29 |
| Proxy statement · Q2 2026 GE HEALTHCARE TECHNOLOGIES INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of 8 director nominees for one | 2026-03-19 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.04 / share ex-date Oct 23, 2026 · pay Nov 13, 2026 | 2026-10-23 |
| Dividend | $0.04 / share ex-date Jul 24, 2026 · pay Aug 14, 2026 | 2026-07-24 |
| Dividend | $0.04 / share ex-date Apr 2, 2026 · pay May 15, 2026 | 2026-04-02 |
| Dividend | $0.04 / share ex-date Jan 9, 2026 · pay Feb 13, 2026 | 2026-01-09 |
| Dividend | $0.04 / share ex-date Oct 24, 2025 · pay Nov 14, 2025 | 2025-10-24 |
| Announcement | Date |
|---|---|
| Issued $1.25B senior notes to finance previously announced Intelerad acquisition GE HealthCare Technologies issued $1.25 billion in senior notes to finance its acquisition of Intelerad Medical Systems. The company sold two tranches: $600 million of 4.150% notes due in 20 | 2025-12-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GE HealthCare Technologies Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.